Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 85%
filed 2026-05-28
Item 5.02
Taylor Patton's appointment as Chief Commercial and Marketing Officer is the principal disclosed action. While Henry L. Charlton's transition to a different senior role is also mentioned, the filing centers on the succession event—Patton succeeding Charlton in a C-suite commercial leadership position. This executive appointment at a major medical device company is material to investors assessing management continuity and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-28
Item 5.02
Red River Bancshares appointed two new directors, A. Peyton Bush, IV and R. Chance DeWitt, M.D., to the board effective May 28, 2026, with independence determinations and committee assignments disclosed.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-28
Item 5.02
The filing discloses the appointment of Eric Batis to the Board of Directors on May 21, 2026, as the principal action. While the section also mentions the resignations of two directors (Stefani Danielle Carter and Rebecca Musser), the substantive focus and detail is on Batis's appointment, his qualifications as COO of Ashford Inc., and his extensive operational and investment background. The appointment of a new board member with significant operational experience at a related company is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-28
Item 5.02
Peter Pitts was appointed as a director of Brainstorm Cell Therapeutics effective May 25, 2026, expanding the Board from seven to eight directors. The appointment was approved by the Board and disclosed via press release on May 28, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-28
Item 5.02
Andrew Safran was appointed to the Board of Directors of Ferrellgas, Inc. on May 21, 2026, bringing significant energy and investment banking experience. Pamela A. Breuckmann was appointed to Vice Chair of the Board. These board appointments and promotion represent material governance changes affecting the company's strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-28
Item 5.02
The filing discloses the appointment of Jason B. Rush as Chairman of the Board on May 27, 2026, following his election to the Board at the May 7, 2026 annual meeting. While Rush was already serving as President and CEO (appointed January 1, 2026), the principal disclosed action here is his elevation to Chairman, a material executive appointment. The extensive employment history and compensation reference underscore the significance of this role change.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-28
Item 7.01
The filing discloses the appointment of Matt McLaughlin as Chief Executive Officer of comScore, Inc., announced via press release on May 28, 2026. The appointment of a CEO is a material executive change that would affect a reasonable investor's assessment of the company's leadership and direction. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-05-28
Item 5.02
Tim McHugh was elected to the Board of Directors of FrontView REIT, Inc., effective May 28, 2026. McHugh brings substantial experience as Co-President and CFO of Welltower Inc., a public REIT, and qualifies as independent under NYSE listing standards.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-28
Item 5.02
Three former American Woodmark directors—Andrew Cogan, Philip Fracassa, and Daniel Hendrix—were appointed as independent directors to MasterBrand's Board effective at the merger closing, expanding the Board from 8 to 11 directors as part of post-acquisition governance integration.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-28
Item 5.02
Scott M. Ferris was appointed as a Class III Director on May 22, 2026, following the Board's decision to increase board size from 8 to 9 members. Ferris was also appointed to the Audit Committee and Operational Risk Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-28
Item 5.02
The filing discloses the appointment of Zachary Roberts, M.D., Ph.D. as President and Chief Executive Officer effective July 1, 2026, replacing David Chang. While the section also covers Dr. Chang's departure and compensatory arrangements for Dr. Roberts, the principal disclosed action centers on the appointment of a new CEO—a material executive change. The filing provides detailed background on Dr. Roberts' qualifications and his appointment to the Board, making the appointment the salient event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-28
Item 5.02
BiomX appointed Roy Rousso as Chief Business Officer effective July 1, 2026, with detailed compensation terms including a monthly consulting fee of $11,900, performance bonus eligibility up to 50%, and an equity award of 200,000 shares vesting over three years. This is a material executive appointment disclosing a senior officer role and significant compensatory arrangements that would affect investor assessment of the company's leadership and capital structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-28
Item 5.02
The filing discloses both the resignation of CFO Lili Hu and the appointment of Wei Li as CFO and Board member effective immediately on May 28, 2026. While both events occur, the principal disclosed action centers on the appointment of Ms. Li to the CFO role and Board, with detailed background on her qualifications and experience. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-28
Item 5.02
While the filing discloses both a director resignation (David Enholm) and an appointment (Tyler Hassen), the principal action is the appointment of the CEO to the Board. The resignation is explicitly stated as amicable and unrelated to disagreement, and Mr. Enholm continues as CFO. The appointment of the sitting CEO to the Board is the material governance event that would affect investor assessment of the company's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-28
Item 5.02
The filing discloses two executive events: the departure of President and CEO David Moon (effective May 26, 2026) and the appointment of Alex Buehler as Interim President and CEO on the same date. While both events are disclosed, the principal action and focus of the disclosure is Buehler's appointment to lead the company during the transition to a permanent successor. The appointment of an interim CEO is material to investors as it addresses continuity of leadership and operational control.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-28
Item 7.01
The filing discloses the appointment of Bradley Williams as Vice President of Government Affairs, a named executive position. The company explicitly states this appointment "supports the Company's vision of establishing the Company as the U.S. leader at the front-end of the nuclear fuel cycle and deepens its presence in Washington, D.C.," indicating strategic importance. While disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment material to investors assessing the company's leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-28
Item 5.02
The Board of Western Digital unanimously appointed Manuvir Das as a director and Audit Committee member on May 26, 2026. This appointment affects the company's corporate governance and oversight structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-28
Item 5.02
EnerSys announced a segment realignment effective May 28, 2026, resulting in material reassignments of executive roles and responsibilities for three named officers: Keith D. Fisher (President, Network & Infrastructure Solutions), Chad C. Uplinger (President, Industrial Mobility Solutions), and Mark E. Matthews (Chief Technology Officer and President, Precision Power Solutions).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-28
Item 5.02
Mitchell Arends was appointed Senior Vice President and Chief Supply Chain Officer, effective June 22, 2026, succeeding Jason Reiman who is retiring from the role. The appointment of an executive to this material operational position is disclosed across Items 5.02 and 7.01.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-28
Item 5.02
The filing discloses the appointment of Andrew Miller, Ph.D. to the Board of Directors on May 27, 2026, following unanimous Board approval. The disclosure includes detailed biographical information highlighting his extensive biotechnology leadership experience (founder of Karuna Therapeutics, former CEO, COO, and current board member of Kyverna Therapeutics), his compensation arrangements (initial and annual equity grants plus cash retainers), and committee assignments. This is a clear executive appointment event material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-27
Item 5.02
The filing discloses the appointment of William Harkins to the role of Executive Vice President and Chief Financial Officer effective June 15, 2026, along with compensatory arrangements including a $610,000 base salary, bonus and equity adjustments, and a $500,000 one-time restricted stock award. While the filing also mentions Kenneth Krause's resignation as CFO, the principal disclosed action centers on Harkins' appointment to a senior executive role with material compensation details, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-27
Item 5.02
The filing discloses the appointment of Stephen J. McAnena as President and Chief Executive Officer effective June 1, 2026, and the election of Tony DeSantis as a non-employee director. While the section also includes details on compensatory arrangements and a new Executive Severance Plan, the principal disclosed action centers on these executive and board appointments. The appointment of a new CEO is a material event that would affect a reasonable investor's assessment of the company's leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-05-27
Item 8.01
Thomas Sweet was appointed by the Board as Chair of the Audit Committee, effective May 26, 2026. This appointment is material given its impact on governance and oversight of internal controls, particularly in light of the company's ongoing remediation of material weaknesses in internal control over financial reporting.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-27
Item 5.02
Agilent appointed Tim Downs as Vice President, Chief Accounting Officer and principal accounting officer, effective May 20, 2026, following the retirement of Rodney Gonsalves.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-05-27
Item 5.02
Mr. Stopko was appointed to a director or officer position. The filing references incorporation by reference to Item 7.01 for substantive disclosure and directs readers to the company's 10-K for details on his role, compensation, and governance status.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-05-27
Item 5.02
Primis Financial Corp. appointed two new directors, Scott R. Gamble and J. Brock Saunders, to the Board of Primis Financial Corp. and its subsidiary bank, effective May 21, 2026, with specified committee assignments. The appointments follow the non-re-election of two departing directors and reflect changes to board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-05-27
Item 5.02
Synopsys appointed Jesse Cohn to its Board of Directors effective June 1, 2026, pursuant to a Cooperation Agreement with Elliott Investment Management dated May 26, 2026. Mr. Cohn was also appointed to the Corporate Governance and Nominating Committee and received standard director compensation and indemnification arrangements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-27
Item 5.02
Ash Walia was appointed as Chief Financial Officer of Six Flags Entertainment Corporation, effective June 17, 2026, with a base salary of $690,000, target annual incentive of 100%, restricted stock units valued at $1,250,000, and annual equity grants of $1,869,000.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-27
Item 5.02
Erik Lundgren was appointed as Chief Executive Officer effective June 1, 2026, with a detailed employment agreement including a base salary of $685,000, performance bonuses, and an equity grant of 1,000,000 options. Dr. Daniel Vitt resigned as CEO concurrent with this appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-27
Item 5.02
Six directors—Joseph Durnford, Ernest Miller, Jon Ryan, Mike Maggard, Dan Collingridge-Padbury, and Jonathan Nickell—were appointed to the board of Oceanhawk in connection with the IPO on May 20, 2026, with assignments to audit and compensation committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-27
Item 5.02
The filing discloses the appointment of Karen Park as a director of Fortress Value Acquisition Corp. V, effective immediately on May 27, 2026, along with her concurrent appointment to the Audit Committee and Compensation Committee. The principal disclosed action is a person taking a role. While the filing also mentions compensatory arrangements (30,000 founder shares), the core event centers on the director appointment itself, which is material to investors as it affects board composition and governance of a SPAC.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-27
Item 5.02
The filing discloses the appointment of Michael Pruitt to the Board of Directors on May 20, 2026. Although the Item 5.02(d) heading references both departures and appointments, the prose centers exclusively on Pruitt's election as a director, with detailed background on his extensive public company leadership experience and expertise in emerging technology. This is a clear director appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-27
Item 5.02
Shimon Steinmetz was appointed as Executive Vice President and Chief Financial Officer, effective on or prior to July 27, 2026, with a base salary of $500,000, bonus targets, RSAs, and PSUs, along with specified severance provisions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-27
Item 5.02
The filing discloses both a director departure (Joseph F. Rossetti's resignation on May 21, 2026) and an appointment (Richard Xie appointed to the Board effective immediately to fill the vacancy). While both events occurred, the substantive focus and length of the disclosure centers on Mr. Xie's appointment, his qualifications, committee assignments (including as Chair of Audit and Compensation Committees), and independence determination. The appointment of a qualified director with significant finance and investment management experience to key committee leadership roles is the principal disclosed action and is material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-27
Item 5.02
David J. Pauli was promoted to Chief Operating Officer (COO) and Daniel J. Klun was promoted to Chief Financial Officer (CFO), both effective immediately, representing material changes to the Company's executive leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-05-27
Item 5.02
The Board of Directors elected Joseph Haniford as a director effective May 22, 2026. This appointment followed the Board's acceptance of resignations from two incumbent directors (Freeman and Tack) who failed to achieve majority re-election votes at the annual meeting.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-27
Item 5.02
Benjamin F. Cravatt, Ph.D. was elected to the Board of Directors effective June 1, 2026, expanding the Board from ten to eleven members and assigned to the Science and Technology Committee. His compensation package includes an annual cash retainer of $75,000 and an initial stock option grant valued at $600,000.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-05-27
Item 5.02
The Board approved on May 20, 2026 the promotion of Curtiss Bruce to Chief Financial & Operating Officer, effective May 21, 2026, expanding his responsibilities to include principal operating officer duties alongside his CFO role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-27
Item 5.02
The Board appointed Pankaj Malik as Interim Chief Financial Officer effective May 29, 2026, with a base salary of $409,013 and target bonus of $205,000.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-27
Item 5.02
The filing discloses the appointment of Shannon Campbell as a Class I director effective May 22, 2026, with the Board expanding from six to seven members. While the disclosure includes compensatory details (annual retainer of $45,000, committee fee of $7,500, and an initial RSU grant of 114,200 shares), the principal action is the director appointment itself, making exec_appointment the most salient classification. Director appointments are material to investors as they affect board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-27
Item 5.02
Five new directors were appointed effective at the closing of the investment transaction, expanding the Board from four to nine members as part of the governance changes accompanying the change of control.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-26
Item 5.02
The filing discloses the appointment of Cindy Hoots to McCormick's Board of Directors effective June 1, 2026, with assignment to the Audit Committee. This is a clear board appointment of a qualified executive (recently retired Chief Digital Officer and CIO of AstraZeneca PLC, current Zoom board member), which is material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-26
Item 8.01
Thomas Sweet was appointed as Chair of the Audit Committee with explicit responsibility for overseeing remediation of material weaknesses in internal controls, a material governance matter affecting financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-26
Item 5.02
Scott Beiser was appointed as a Class I director of Palomar Holdings, Inc., effective immediately, to serve until the 2029 Annual Meeting. The appointment was disclosed in Item 5.02 and furnished via press release in Item 7.01.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-26
Item 5.02
Four directors—Shahal M. Khan, Leon Golden, Scott E. Young, and Sergey Alekseev—were appointed to the board of BurTech in connection with the IPO on May 21, 2026, with assignments to key board committees including Audit, Compensation, and Nominating and Corporate Governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-26
Item 5.02
Dropbox appointed Ashraf Alkarmi as Co-Chief Executive Officer and Board member effective May 26, 2026, with Andrew Houston transitioning to Executive Chairman. Michael Torres was also appointed as Chief Product Officer as part of the leadership restructuring.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-26
The filing discloses the appointment of Andrew Penn as a member and Chair of the Board of Directors of SharonAI Holdings Inc., effective May 21, 2026. The disclosure includes Penn's extensive background as former CEO of Telstra Corporation Limited and AXA Asia Pacific Holdings, along with his current roles and honors. The appointment is accompanied by a Director Appointment Letter detailing equity compensation (40,000 initial RSUs plus 6,944 annual RSUs) and $165,000 annual cash compensation. This is a material executive appointment that would affect a reasonable investor's assessment of the company's governance and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-26
Item 5.02
Anthony Catalano was appointed as Chief Operating Officer on May 14, 2026, with a detailed employment agreement specifying $400,000 base salary, $50,000 sign-on bonus, equity awards of 0.30% of outstanding shares, and severance provisions. While the section also mentions Michael Miller's transition to Chief Technology and Products Officer, the principal disclosed action centers on Catalano's appointment to a C-suite role with material compensation and equity arrangements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-26
Item 7.01
Anthony Freve was appointed as Chief Supply Chain Officer effective June 1, 2026, succeeding Paul R. Hibbert in this key operational leadership role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-05-26
Item 5.02
Nicholas Johnson was appointed as Chief Executive Officer of Medifast Inc., effective June 1, 2026, succeeding Daniel R. Chard who transitions to non-executive Chairman. The appointment was approved by the Board on May 20, 2026, and disclosed via press release.
View raw filing on EDGAR →